SCHEMBL5500638

SCHEMBL5500638

O=C(Nc1ccc(Nc2ncc(-c3ccsc3)cn2)cc1)N1CCOCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.53
GAA P10253 3/20 0.53
MAPT P10636 1/20 0.53
HPGD P15428 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
HPGDS O60760 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
NPC1 O15118 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
RAB9A P51151 2/20 0.46
TP53 P04637 1/20 0.46
ESR2 Q92731 1/20 0.46
BLM P54132 1/20 0.46
JAK2 O60674 2/20 0.45
FLT3 P36888 2/20 0.45
MLYCD O95822 1/20 0.45
HSD17B10 Q99714 2/20 0.44
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5495338 0.88 KDM4E (0.47) SMN1; SMN2MAPTJAK2FLT3KDM4E
SCHEMBL5494719 0.84 ATM (0.52) SMN1; SMN2MAPTHPGDNPC1KDM4E
SCHEMBL5495853 0.83 CYP3A4 (0.48) MAPTCYP2C19MEN1KMT2ATP53
SCHEMBL5499160 0.82 SYK (0.53) MAPTNPC1RAB9ATP53JAK2
SCHEMBL5495846 0.81 SMN1; SMN2 (0.55) SMN1; SMN2GAAMAPTTSHRLMNA
SCHEMBL5499148 0.80 MEN1 (0.43) SMN1; SMN2GAAMAPTCYP2C19MEN1
SCHEMBL5501205 0.78 CTSC (0.62) SMN1; SMN2MAPTCYP2C9CYP2C19NPC1
SCHEMBL5499872 0.78 THRB (0.50) GAAMAPTTP53LMNA
SCHEMBL5502604 0.77 SYK (0.54) MAPTTP53JAK2MAPK1
SCHEMBL5499974 0.76 KDM4E (0.49) GAAMAPTHPGDNPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US claimed
EP-1753750-A1 THIOPHENE HETEROARYL AMINES Sugen, Inc. (US) 2007-02-21 EP claimed
WO-2005113548-A1 THIOPHENE HETEROARYL AMINES SUGEN, INC. (US) 2005-12-01 WO claimed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
EP-1753750-A1 THIOPHENE HETEROARYL AMINES Sugen, Inc. (US) 2007-02-21 EP disclosed
WO-2005113548-A1 THIOPHENE HETEROARYL AMINES SUGEN, INC. (US) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293484-A1 Thiophene Heteroaryl Amines TTK, CHEK2, ABL1 SMN1; SMN2 3601/4885GAA 2608/4885MAPT 1768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.